Health care providers who treat acute myeloid leukemia (AML) have seen several agents approved in the United States in recent years, including FLT3 inhibitors, IDH inhibitors, a liposomal formulation of cytarabine/daunorubicin, a BCL-2 inhibitor, an anti-CD33 antibody-drug conjugate, a hedgehog signaling inhibitor, and oral azacytidine in the maintenance setting. While the expanding arsenal of therapies available for patients with AML allows practitioners to further hone treatment and individualize care, the complexity of treatment decision-making requires careful consideration of potential risks and benefits of each treatment option.  This real-world, case-based program will provide a format for community hematology-oncologists to hear current updates on the latest targeted therapies in AML and engage in pointed, practical discussions on how to best integrate these data into current and local AML treatment paradigms. 

This educational program is directed toward community-based medical oncologists, hematologic oncologists, hematologists, hematopathologists, BMT specialists, NP/PAs, nurses, and pharmacists, other healthcare professionals involved in the treatment of AML.